FLOT clinical trials

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

This study looks at a new way to treat early oesophageal cancer using a combination of immunotherapy (durvalumab), chemotherapy, and radiotherapy. The aim is to help patients avoid major surgery, while still effectively treating their cancer.